Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030- Product Image

Sale

Global T-Cell Immunotherapy Market by Mechanism Of Action (Active Immunotherapy, Passive Immunotherapy), Product Class (Bispecific Antibodies, Cytokines, Monoclonal Antibodies), Type of Therapy, Indication - Forecast 2024-2030

Report
180 Pages
March 2024
Region: Global
360iResearch™
ID: 4986070

UP TO €851EUR$875USD£729GBP OFF until Dec 31^st 2024

The T-Cell Immunotherapy Market size was estimated at USD 6.81 billion in 2023, USD 7.74 billion in 2024, and is expected to grow at a CAGR of 14.12% to reach USD 17.17 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the T-Cell Immunotherapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the T-Cell Immunotherapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the T-Cell Immunotherapy Market, highlighting leading vendors and their innovative profiles. These include Adaptimmune Therapeutics PLC, Alaunos Therapeutics, Inc., Apac Biotech, Atara Biotherapeutics, Inc., Autolus Therapeutics PLC, bluebird bio, Inc., Bristol-Myers Squibb Company, CARsgen Therapeutics Holdings Limited, Cellectis SA, Chimera Bioengineering, Dendreon Pharmaceuticals LLC, Eureka Therapeutics, Inc., Gilead Sciences, Inc., Green Cross Corporation, Innovative Cellular Therapeutics, Iovance Biotherapeutics, Inc., LAVA Therapeutics N.V., Lyell Immunopharma, Inc., Neogene Therapeutics, Inc., NeoTX Therapeutics Ltd., Novartis AG, Oxford Vacmedix UK Limited, Poseida Therapeutics, Inc., TScan Therapeutics, Inc., and Xenetic Biosciences, Inc.

Market Segmentation & Coverage

This research report categorizes the T-Cell Immunotherapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

Mechanism Of Action
- Active Immunotherapy
- Passive Immunotherapy
Product Class
- Bispecific Antibodies
- Cytokines
- Monoclonal Antibodies
- Oncolytic Virus Therapy
Type of Therapy
- CAR-T
- TCR
- TIL
Indication
- B-cell Malignancies
- Liver Cancer
- Prostate Cancer
- Renal Cell Carcinoma

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the T-Cell Immunotherapy Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the T-Cell Immunotherapy Market?
What are the technology trends and regulatory frameworks in the T-Cell Immunotherapy Market?
What is the market share of the leading vendors in the T-Cell Immunotherapy Market?
Which modes and strategic moves are suitable for entering the T-Cell Immunotherapy Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. T-Cell Immunotherapy Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing Prevalence of Cancer and Autoimmune Diseases
5.1.1.2. Use of Cell-Based Targeted Therapies
5.1.1.3. Increasing R&D Supporting T-cell Immunotherapy
5.1.2. Restraints
5.1.2.1. High Cost of Treatment
5.1.3. Opportunities
5.1.3.1. Commercialisation and Funding by Pharmaceutical Companies
5.1.3.2. Attractiveness of Off-the-Shelf Therapies
5.1.4. Challenges
5.1.4.1. Neurologic Toxicities and Cytokine Release Syndrome
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. T-Cell Immunotherapy Market, by Mechanism Of Action

6.1. Introduction
6.2. Active Immunotherapy
6.3. Passive Immunotherapy

7. T-Cell Immunotherapy Market, by Product Class

7.1. Introduction
7.2. Bispecific Antibodies
7.3. Cytokines
7.4. Monoclonal Antibodies
7.5. Oncolytic Virus Therapy

8. T-Cell Immunotherapy Market, by Type of Therapy

8.1. Introduction
8.2. CAR-T
8.3. TCR
8.4. TIL

9. T-Cell Immunotherapy Market, by Indication

9.1. Introduction
9.2. B-cell Malignancies
9.3. Liver Cancer
9.4. Prostate Cancer
9.5. Renal Cell Carcinoma

10. Americas T-Cell Immunotherapy Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific T-Cell Immunotherapy Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa T-Cell Immunotherapy Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. Adaptimmune Therapeutics PLC
14.1.2. Alaunos Therapeutics, Inc.
14.1.3. Apac Biotech
14.1.4. Atara Biotherapeutics, Inc.
14.1.5. Autolus Therapeutics PLC
14.1.6. bluebird bio, Inc.
14.1.7. Bristol-Myers Squibb Company
14.1.8. CARsgen Therapeutics Holdings Limited
14.1.9. Cellectis SA
14.1.10. Chimera Bioengineering
14.1.11. Dendreon Pharmaceuticals LLC
14.1.12. Eureka Therapeutics, Inc.
14.1.13. Gilead Sciences, Inc.
14.1.14. Green Cross Corporation
14.1.15. Innovative Cellular Therapeutics
14.1.16. Iovance Biotherapeutics, Inc.
14.1.17. LAVA Therapeutics N.V.
14.1.18. Lyell Immunopharma, Inc.
14.1.19. Neogene Therapeutics, Inc.
14.1.20. NeoTX Therapeutics Ltd.
14.1.21. Novartis AG
14.1.22. Oxford Vacmedix UK Limited
14.1.23. Poseida Therapeutics, Inc.
14.1.24. TScan Therapeutics, Inc.
14.1.25. Xenetic Biosciences, Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. T-CELL IMMUNOTHERAPY MARKET RESEARCH PROCESS
FIGURE 2. T-CELL IMMUNOTHERAPY MARKET SIZE, 2023 VS 2030
FIGURE 3. T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. T-CELL IMMUNOTHERAPY MARKET DYNAMICS
FIGURE 7. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2030 (%)
FIGURE 8. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2030 (%)
FIGURE 10. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2030 (%)
FIGURE 12. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 14. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. T-CELL IMMUNOTHERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. T-CELL IMMUNOTHERAPY MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL T-CELL IMMUNOTHERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 6. T-CELL IMMUNOTHERAPY MARKET SIZE, BY ACTIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PASSIVE IMMUNOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 9. T-CELL IMMUNOTHERAPY MARKET SIZE, BY BISPECIFIC ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. T-CELL IMMUNOTHERAPY MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. T-CELL IMMUNOTHERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. T-CELL IMMUNOTHERAPY MARKET SIZE, BY ONCOLYTIC VIRUS THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 14. T-CELL IMMUNOTHERAPY MARKET SIZE, BY CAR-T, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TCR, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. T-CELL IMMUNOTHERAPY MARKET SIZE, BY TIL, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 18. T-CELL IMMUNOTHERAPY MARKET SIZE, BY B-CELL MALIGNANCIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. T-CELL IMMUNOTHERAPY MARKET SIZE, BY LIVER CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. T-CELL IMMUNOTHERAPY MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. T-CELL IMMUNOTHERAPY MARKET SIZE, BY RENAL CELL CARCINOMA, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 23. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 24. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 27. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 28. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 29. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 30. ARGENTINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 32. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 33. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 34. BRAZIL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 35. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 36. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 37. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 38. CANADA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 39. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 40. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 41. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 42. MEXICO T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 43. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 44. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 45. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 46. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. UNITED STATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 48. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 50. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. ASIA-PACIFIC T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 53. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 54. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 55. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 56. AUSTRALIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 58. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 59. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 60. CHINA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 61. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 62. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 63. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 64. INDIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 65. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 66. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 67. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 68. INDONESIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 70. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 71. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 72. JAPAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 73. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 74. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 75. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 76. MALAYSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 77. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 78. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 79. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 80. PHILIPPINES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 81. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 82. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 83. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 84. SINGAPORE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 85. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 86. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 87. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 88. SOUTH KOREA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 90. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 91. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 92. TAIWAN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 93. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 94. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 95. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 96. THAILAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 97. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 98. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 99. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 100. VIETNAM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 106. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 107. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 108. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 109. DENMARK T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 110. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 111. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 112. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 113. EGYPT T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 115. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 116. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 117. FINLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 119. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 120. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 121. FRANCE T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 122. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 123. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 124. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 125. GERMANY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 126. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 127. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 128. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 129. ISRAEL T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 131. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 132. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 133. ITALY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 134. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 135. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 136. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 137. NETHERLANDS T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 138. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 139. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 140. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 141. NIGERIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 143. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 144. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 145. NORWAY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 146. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 147. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 148. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 149. POLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 151. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 152. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 153. QATAR T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 155. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 156. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 157. RUSSIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 158. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 160. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 162. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 164. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 167. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 168. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 169. SPAIN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 171. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 172. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 173. SWEDEN T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 174. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 175. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 176. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 177. SWITZERLAND T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 178. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 179. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 180. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 181. TURKEY T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 186. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY MECHANISM OF ACTION, 2018-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY PRODUCT CLASS, 2018-2030 (USD MILLION)
TABLE 188. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY TYPE OF THERAPY, 2018-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM T-CELL IMMUNOTHERAPY MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. T-CELL IMMUNOTHERAPY MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 191. T-CELL IMMUNOTHERAPY MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. T-CELL IMMUNOTHERAPY MARKET LICENSE & PRICING

Companies Mentioned

Adaptimmune Therapeutics PLC
Alaunos Therapeutics, Inc.
Apac Biotech
Atara Biotherapeutics, Inc.
Autolus Therapeutics PLC
bluebird bio, Inc.
Bristol-Myers Squibb Company
CARsgen Therapeutics Holdings Limited
Cellectis SA
Chimera Bioengineering
Dendreon Pharmaceuticals LLC
Eureka Therapeutics, Inc.
Gilead Sciences, Inc.
Green Cross Corporation
Innovative Cellular Therapeutics
Iovance Biotherapeutics, Inc.
LAVA Therapeutics N.V.
Lyell Immunopharma, Inc.
Neogene Therapeutics, Inc.
NeoTX Therapeutics Ltd.
Novartis AG
Oxford Vacmedix UK Limited
Poseida Therapeutics, Inc.
TScan Therapeutics, Inc.
Xenetic Biosciences, Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	180
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 7.74 Billion
Forecasted Market Value ( USD ) by 2030	$ 17.17 Billion
Compound Annual Growth Rate	14.1%
Regions Covered	Global
No. of Companies Mentioned	25

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3283EUR$3,374USD£2,812GBP €3648EUR$3,749USD£3,125GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4159EUR$4,274USD£3,562GBP €4621EUR$4,749USD£3,958GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5034EUR$5,174USD£4,313GBP €5594EUR$5,749USD£4,792GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5910EUR$6,074USD£5,063GBP €6567EUR$6,749USD£5,625GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7661EUR$7,874USD£6,563GBP €8513EUR$8,749USD£7,292GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Global Cellular Immunotherapy Market by Type (CAR T-Cell Therapy, Dendritic Cell Therapy, NK Cell Therapy), Indication (B-Cell Malignancies, Liver Cancer, Prostate Cancer), Technology Type, End-Use - Forecast 2024-2030

Global Cancer Immunotherapy Market by Product (Cell Therapies, Checkpoint Inhibitors, Immunomodulators), Function (Breast Cancer, Colorectal Cancer, Head & Neck Cancer), End-User - Forecast 2024-2030

Global T-Cell Immunotherapy Market (2023-2028) Competitive Analysis, Impact of Economic Slowdown & Impending Recession, Ansoff Analysis

Cellular Immunotherapy Global Market Report 2024

Cell-Based Immunotherapy Market - Growth, Trends, and Forecasts (2023 - 2028)

About the T Cell Immunotherapy Market